Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland.
CTU Bern, University of Bern, Bern, Switzerland.
JACC Cardiovasc Interv. 2021 Oct 25;14(20):2246-2256. doi: 10.1016/j.jcin.2021.07.030. Epub 2021 Sep 29.
The aims of this study were to document the prevalence of concomitant tricuspid regurgitation (TR) before and after transcatheter aortic valve replacement (TAVR), to quantify potential eligibility for transcatheter tricuspid valve intervention (TTVI), and to report clinical outcomes as a function of the severity of TR and potential candidacy for TTVI.
The importance of concomitant TR in patients with severe aortic stenosis undergoing TAVR remains unclear.
In a prospective TAVR registry, the severity of TR before and after TAVR was retrospectively evaluated in an echocardiography core laboratory.
Among 2,008 eligible patients, 1,659 patients (82.6%) had mild or less TR, 242 (12.1%) had moderate TR, 57 (2.8%) had severe TR, and 50 (2.5%) had massive TR. More than one-half of patients with moderate or greater TR had a reduction in TR, while a small proportion of patients with severe or less of TR had worsening of TR after TAVR. In contrast to TR at baseline, severe TR (adjusted HR [HR]: 1.90; 95% CI: 1.03-3.49) and massive TR (HR: 2.17; 95% CI: 1.10-4.30) after TAVR conferred an increased risk for mortality compared with mild or less TR at 1 year after TAVR. After TAVR, 63 patients (3.1%) were deemed potential candidates for TTVI. They had a 2-fold increased risk for mortality between 30 days and 1 year (HR: 1.93; 95% CI: 1.15-3.25) and a higher risk for persistent heart failure symptoms (adjusted risk ratio: 2.80; 95% CI: 1.78-4.40).
A non-negligible proportion of patients were considered potential candidates for TTVI after TAVR and had impaired prognosis and persistently impaired functional status at 1 year. (SwissTAVI Registry; NCT01368250).
本研究旨在记录经导管主动脉瓣置换术(TAVR)前后三尖瓣反流(TR)的发生率,评估潜在的经导管三尖瓣介入治疗(TTVI)适应证,并根据 TR 严重程度和 TTVI 适应证报告临床结局。
在接受 TAVR 的严重主动脉瓣狭窄患者中,并发 TR 的重要性尚不清楚。
在一项前瞻性 TAVR 注册研究中,回顾性地在超声心动图核心实验室评估 TAVR 前后 TR 的严重程度。
在 2008 例合格患者中,1659 例(82.6%)为轻度或以下 TR,242 例(12.1%)为中度 TR,57 例(2.8%)为重度 TR,50 例(2.5%)为重度 TR。超过一半的中度或重度 TR 患者的 TR 得到了改善,而一小部分轻度或以下 TR 的患者在 TAVR 后出现了 TR 的恶化。与基线 TR 相比,TAVR 后重度 TR(校正 HR [HR]:1.90;95%CI:1.03-3.49)和重度 TR(HR:2.17;95%CI:1.10-4.30)与 TAVR 后 1 年的死亡率增加相关。TAVR 后,有 63 例(3.1%)患者被认为是 TTVI 的潜在适应证。与 TAVR 后 30 天至 1 年期间的轻度或以下 TR 患者相比,他们的死亡率增加了 2 倍(HR:1.93;95%CI:1.15-3.25),且持续性心力衰竭症状的风险更高(校正风险比:2.80;95%CI:1.78-4.40)。
TAVR 后相当一部分患者被认为是 TTVI 的潜在适应证,他们在 1 年内预后不良,且持续存在功能状态受损。(瑞士 TAVR 注册研究;NCT01368250)